Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by JLGeminion Sep 02, 2010 12:40pm

509 Views

Post# 17408572

RE: RE: Goods News - Impressive Pop?

The market valuation for Oncolytics, even with the current pop in the stock price, is still around $200 million. I am not impressed. A $200 million valuation for a Company with the property rights to Reolysin and the potential of Reolysin in the fight against cancer is a joke. The potential market valuation within the next two years exceeds $1 biilion. I will only be impressed when I see signs of the manipulators loosing control of the market price below $5.00. Today's announcement adds to their growing problems to control the price.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages